BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 27811854)

  • 21. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes.
    Limsui D; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Harnack LJ; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
    J Natl Cancer Inst; 2010 Jul; 102(14):1012-22. PubMed ID: 20587792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer.
    Tanaka H; Deng G; Matsuzaki K; Kakar S; Kim GE; Miura S; Sleisenger MH; Kim YS
    Int J Cancer; 2006 Jun; 118(11):2765-71. PubMed ID: 16381005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
    J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
    Van Rijnsoever M; Elsaleh H; Joseph D; McCaul K; Iacopetta B
    Clin Cancer Res; 2003 Aug; 9(8):2898-903. PubMed ID: 12912934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
    Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
    Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features.
    Ang PW; Loh M; Liem N; Lim PL; Grieu F; Vaithilingam A; Platell C; Yong WP; Iacopetta B; Soong R
    BMC Cancer; 2010 May; 10():227. PubMed ID: 20492682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China.
    Li X; Hu F; Wang Y; Yao X; Zhang Z; Wang F; Sun G; Cui BB; Dong X; Zhao Y
    Biomed Res Int; 2014; 2014():236361. PubMed ID: 25243122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
    Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
    BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
    Whitehall VL; Dumenil TD; McKeone DM; Bond CE; Bettington ML; Buttenshaw RL; Bowdler L; Montgomery GW; Wockner LF; Leggett BA
    Epigenetics; 2014 Nov; 9(11):1454-60. PubMed ID: 25496513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
    Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
    Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
    Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
    Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.
    Bae JM; Kim JH; Cho NY; Kim TY; Kang GH
    Br J Cancer; 2013 Aug; 109(4):1004-12. PubMed ID: 23900220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.
    Barault L; Charon-Barra C; Jooste V; de la Vega MF; Martin L; Roignot P; Rat P; Bouvier AM; Laurent-Puig P; Faivre J; Chapusot C; Piard F
    Cancer Res; 2008 Oct; 68(20):8541-6. PubMed ID: 18922929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer.
    Liu J; Tang L; Yi J; Li G; Lu Y; Xu Y; Zhao S; Mao R; Li X; Ren L; Wang K
    BMC Gastroenterol; 2019 Nov; 19(1):173. PubMed ID: 31690257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer.
    Advani SM; Swartz MD; Loree J; Davis JS; Sarsashek AM; Lam M; Lee MS; Bressler J; Lopez DS; Daniel CR; Morris V; Shureqi I; Kee B; Dasari A; Vilar E; Overman M; Hamilton S; Maru D; Braithwaite D; Kopetz S
    Clin Colorectal Cancer; 2021 Jun; 20(2):137-147.e1. PubMed ID: 33229221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review.
    Jia M; Gao X; Zhang Y; Hoffmeister M; Brenner H
    Clin Epigenetics; 2016; 8():25. PubMed ID: 26941852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort.
    Chen KH; Lin LI; Yuan CT; Tseng LH; Chao YL; Liang YH; Liang JT; Lin BR; Cheng AL; Yeh KH
    Br J Cancer; 2021 Jul; 125(1):48-54. PubMed ID: 33846524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Jun; 38(6):842-9. PubMed ID: 17350669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.